Brigatinib and Lopid
Determining the interaction of Brigatinib and Lopid and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.
Professional:Gemfibrozil, a potent CYP450 2C8 inhibitor, has been reported to decrease (rather than increase) the plasma concentrations of brigatinib, which is a substrate of the isoenzyme in vitro. When a single 90 mg dose of brigatinib was administered with gemfibrozil (600 mg twice daily), brigatinib peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 41% and 12%, respectively, compared to brigatinib administered alone. These changes are not considered clinically relevant. The mechanism of interaction is unknown.
- "Product Information. Alunbrig (brigatinib)." Ariad Pharmaceuticals Inc, Cambridge, MA.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Brigatinib-Lopinavir and ritonavir
- Brigatinib-Lopinavir and Ritonavir Oral Solution
- Brigatinib-Lopinavir and Ritonavir Solution
- Brigatinib-Lopinavir and Ritonavir Tablets
- Brigatinib-Lopreeza
- Brigatinib-Lopressor
- Lopid-Brilinta
- Lopid-Brilinta Tablets
- Lopid-Brimonidine
- Lopid-Brimonidine and brinzolamide ophthalmic
- Lopid-Brimonidine and Timolol
- Lopid-Brimonidine and timolol ophthalmic